U.S. Interactive Media and Services Stock News

NasdaqGS:PRDO
NasdaqGS:PRDOConsumer Services

Assessing Perdoceo Education’s (PRDO) Valuation After Earnings Growth Guidance And Dividend Affirmation

Perdoceo Education (PRDO) drew fresh attention after reporting fourth quarter and full year 2025 earnings, issuing new 2026 guidance, and affirming its quarterly dividend, giving investors several data points to reassess the stock. See our latest analysis for Perdoceo Education. The recent earnings, 2026 guidance and dividend affirmation come after a period of steady share price strength, with a 90 day share price return of 19.83% and a 1 year total shareholder return of 32.10% supporting a...
NYSE:UCB
NYSE:UCBBanks

Assessing Whether United Community Banks (UCB) Still Looks Undervalued After Recent Share Price Weakness

Without a specific news announcement driving attention today, United Community Banks (UCB) still offers investors concrete data points to consider, including recent share performance, profitability metrics, and value-focused scores. See our latest analysis for United Community Banks. At a share price of $32.17, United Community Banks has seen a 6.56% 1 month share price decline, while its 90 day share price return of 3.91% and 1 year total shareholder return of 3.10% point to relatively...
NYSE:GKOS
NYSE:GKOSMedical Equipment

Glaukos (GKOS) Valuation Check As iDose Sales Momentum Meets Impairment Charge And Upbeat 2026 Outlook

Glaukos (GKOS) is back in focus after its fourth quarter 2025 report paired strong sales figures with a sizeable impairment charge, followed shortly by fresh 2026 sales guidance and a new ESOP related shelf registration. See our latest analysis for Glaukos. The recent impairment charge and ESOP related shelf registration come against a backdrop of steady share price gains, with a 90 day share price return of 13.28% and a very large 3 year total shareholder return of 139.03%. This suggests...
NasdaqGS:XERS
NasdaqGS:XERSPharmaceuticals

Xeris Biopharma Holdings (XERS) Is Down 7.4% After Suing to Block Recorlev Generics Until 2040

Xeris Biopharma recently filed a Hatch-Waxman patent infringement lawsuit in the US District Court for the District of New Jersey against Torrent Pharmaceuticals and Somerset Therapeutics, seeking to block generic versions of its Cushing’s syndrome therapy Recorlev until its patents expire in March 2040. This legal move highlights how central Recorlev’s intellectual property protection is to Xeris’s long-term product exclusivity and potential revenue longevity in its endocrine...
NYSE:SEE
NYSE:SEEPackaging

Assessing Sealed Air (SEE) Valuation As Shares Trade Near Recent Levels

Why Sealed Air is on investors’ radar today Sealed Air (SEE) is back in focus after recent trading left the shares around $41.88, prompting investors to reassess how its packaging business and current valuation line up with their expectations. See our latest analysis for Sealed Air. While the 1-day and 7-day share price returns are slightly negative, Sealed Air’s 1-year total shareholder return of 25.46% contrasts with weaker 3-year and modest 5-year total shareholder returns, which suggests...
NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

Is EyePoint (EYPT) Recasting Its Ophthalmology Playbook With a Veteran Launch Executive at DURAVYU?

EyePoint, Inc. recently appointed Michael Campbell as Chief Commercial Officer, giving him responsibility for commercial strategy and launch preparation for DURAVYU, its Phase 3 retinal disease candidate. The hire brings in a leader who helped shape the commercial playbooks behind Lucentis, Xiidra, Beovu and Tyrvaya, directly relevant to DURAVYU’s target markets. We’ll now examine how adding a veteran ophthalmology launch executive to oversee DURAVYU’s commercialization may influence...
NYSE:EMR
NYSE:EMRElectrical

Emerson Electric (EMR) Valuation Check After Q1 2026 Beat And Raised EPS Outlook

Emerson Electric (EMR) is back on investors’ radar after its Q1 2026 earnings report and a higher full year EPS forecast, with management pointing to electrification and nearshoring as key demand drivers. See our latest analysis for Emerson Electric. The Q1 earnings beat and raised EPS guidance arrived after a strong run, with a 90 day share price return of 14.26% and a 1 year total shareholder return of 26.02%, suggesting momentum has been building over both shorter and longer periods. If...
NasdaqGS:OMCL
NasdaqGS:OMCLMedical Equipment

Should Omnicell’s Shift Toward Software and Services Require Action From Omnicell (OMCL) Investors?

Omnicell has recently accelerated its shift from hardware-focused sales toward software and services, including acquiring ANiGENT in October 2025 to broaden its drug diversion detection capabilities and recurring revenue base. This pivot toward subscription-like revenue streams is prompting investors to reassess Omnicell less as a traditional equipment maker and more as a healthcare IT provider, with different expectations for growth, risk and valuation. Next, we’ll examine how Omnicell’s...
NYSE:ENS
NYSE:ENSElectrical

What EnerSys (ENS)'s New Mid‑Cap Fund Backing and Buyback Focus Means For Shareholders

In Q4 2025, Harbor Capital Advisors' Mid Cap Value Fund disclosed that it had initiated a new position in EnerSys, citing improving operating margins, sales growth, strong cash flow, ongoing share buybacks, and regular dividend payments as key reasons for the investment. The fund also ranked EnerSys in the top 5% of its evaluation universe, highlighting how the company’s combination of operating momentum and capital returns screens well against a broad mid-cap peer group. Next, we’ll examine...
NasdaqGS:VLY
NasdaqGS:VLYBanks

A Look At Valley National Bancorp (VLY) Valuation After Inflation Jitters And Credit Risk Concerns

Valley National Bancorp (VLY) shares dropped 6.2% as hotter inflation data and growing credit risk worries pressured regional lenders, even though the bank confirmed regular dividends and a new share repurchase authorization. See our latest analysis for Valley National Bancorp. Despite the latest 5.7% one day share price decline to US$12.61, Valley National Bancorp’s 90 day share price return of 9.8% and 1 year total shareholder return of 34.0% suggest momentum has generally been positive...
NYSE:ACA
NYSE:ACAConstruction

Assessing Arcosa (ACA) Valuation After Recent Share Pullback And Conflicting Fair Value Signals

Arcosa (ACA) is back on investors’ radar after a recent share pullback over the past week and month, drawing attention to how its infrastructure focused business and current valuation metrics stack up today. See our latest analysis for Arcosa. The sharp 1 day share price decline of 15.7% and 7 day share price return of 14.9% sit against a 1 year total shareholder return of 28.42% and 5 year total shareholder return of 84.39%. This suggests recent momentum has cooled after a strong multi year...
NYSE:LADR
NYSE:LADRMortgage REITs

How Ladder’s New US$1.25 Billion Unsecured Facility And Term Loan At Ladder Capital (LADR) Has Changed Its Investment Story

In February 2026, Ladder Capital Corp. announced it had secured US$675 million in new unsecured capital commitments, expanding its unsecured revolving credit facility to US$1.25 billion and adding a US$275 million unsecured delayed draw term loan priced at 140 basis points over SOFR. This package of same-day liquidity at 125 basis points over SOFR and long-dated funding to 2030 materially strengthens Ladder’s funding flexibility and duration profile. Next, we’ll examine how this expanded...
NasdaqGS:REG
NasdaqGS:REGRetail REITs

Regency Centers Note Sale Sparks Fresh Questions On Debt And Valuation

Regency Centers completed a public offering of $450 million in senior unsecured notes due 2033. The issuance is intended to support balance sheet optimization and ongoing development activities. The company trades on the NasdaqGS under the ticker NasdaqGS:REG, with a current share price of $79.0. For investors watching NasdaqGS:REG, this $450 million notes offering is a fresh data point on how Regency Centers is managing its capital structure. The stock is at $79.0, with returns of 2.8%...
NasdaqGS:LPLA
NasdaqGS:LPLACapital Markets

A Look At LPL Financial Holdings (LPLA) Valuation After Recent Share Price Weakness

LPL Financial Holdings (LPLA) has drawn attention after a period of weaker share performance, with returns over the past month, past 3 months, and year all in negative territory, even though multi year total returns remain positive. See our latest analysis for LPL Financial Holdings. The recent 1 month share price return of a 17.59% decline and year to date share price return of a 16.94% decline point to fading near term momentum, even though the 5 year total shareholder return of 129.88%...
NYSE:OC
NYSE:OCBuilding

Owens Corning Losses Spur Questions On Earnings Recovery And Valuation

Owens Corning (NYSE:OC) reported a net loss for the fourth quarter, reversing net income from the same period a year earlier. The company also posted a full year net loss, a material deterioration compared with the prior year's profitability. Recent results came in below earnings expectations, highlighting weaker than anticipated financial performance. For investors watching NYSE:OC, this shift to losses comes with the stock recently closing at $122.07. Shares are down 8.0% over the past...
NYSE:BCC
NYSE:BCCTrade Distributors

Is Boise Cascade (BCC) Fairly Priced After Housing Demand Headlines And Recent Share Pullback

If you are wondering whether Boise Cascade's share price still reflects its real worth, looking at how the market has treated the stock over different time frames is a useful starting point. The stock last closed at US$82.74, with returns of 0.7% over 7 days, 3.0% over 30 days, 11.6% year to date, but a 19.3% decline over 1 year and longer term returns of 36.4% over 3 years and 107.2% over 5 years. Recent headlines around Boise Cascade have focused on its position as a major supplier of...
NasdaqGM:NTLA
NasdaqGM:NTLABiotechs

Intellia Trial Milestones Refocus Attention On Gene Editing Risk And Reward

FDA lifts clinical hold on Intellia Therapeutics' MAGNITUDE-2 ATTR amyloidosis trial, allowing global enrollment to resume with updated safety protocols. Intellia completes phase 3 enrollment ahead of schedule in the HAELO trial for lonvo-z, a one time gene editing therapy for hereditary angioedema. These steps advance Intellia Therapeutics' late stage pipeline and move its gene editing candidates closer to potential approval and commercialization. For investors watching Intellia...
NasdaqGS:LINE
NasdaqGS:LINEIndustrial REITs

Is It Time To Reassess Lineage (LINE) After Recent Real Estate Sector Rethink?

If you are trying to work out whether Lineage at around US$40.52 is a bargain or just fairly priced, you are in the right place. The stock has recently posted returns of 5.8% over 7 days, 12.6% over 30 days and 14.4% year to date, although the 1 year return sits at a 29.3% decline. Recent attention on Lineage has focused on its position in the US real estate space and how investors are reassessing companies in the sector, which helps frame these recent price moves. Coverage has regularly...
NYSE:THR
NYSE:THRElectrical

Thermon Buyout By CECO Sparks Valuation Questions And Fairness Reviews

Thermon Group Holdings (NYSE:THR) has entered into a definitive agreement to be acquired by CECO Environmental Corp. in a cash and stock deal. The transaction proposes different forms of consideration for existing Thermon shareholders, subject to customary approvals. Law firms have launched investigations into whether the terms of the acquisition are fair to Thermon shareholders. Thermon shares most recently closed at $50.78, with the stock showing returns of 34.9% year to date and 72.1%...
NYSE:WRBY
NYSE:WRBYSpecialty Retail

Is It Time To Reassess Warby Parker (WRBY) After Its Google Partnership And Recent Rally?

Wondering if Warby Parker at around US$25.01 is priced for its brand story or for its actual fundamentals? This article breaks down what the current share price may be implying about value. The stock has had a mixed run, with a 5.5% return over the past week, a 2.0% decline over the last 30 days, a 10.6% return year to date and a 1.1% return over the past year, while the 3 year return sits at 100.4%. Recent headlines around Warby Parker have focused on its position in the US eyewear retail...
NYSE:H
NYSE:HHospitality

Hyatt Leadership Shift Raises Governance And Reputational Questions For Investors

Hyatt Hotels (NYSE:H) announced the retirement of Executive Chairman Thomas J. Pritzker after more than two decades in the role. The move comes alongside public mention of Pritzker's past association with Jeffrey Epstein and Ghislaine Maxwell. Hyatt has appointed current CEO Mark S. Hoplamazian as the new Chairman, concentrating leadership in a single figure. The transition highlights both succession planning and governance considerations for the company. For you as an investor, the key...
NYSE:WTRG
NYSE:WTRGWater Utilities

Essential Utilities Merger With American Water Puts Valuation And Risks In Focus

Essential Utilities (NYSE:WTRG) has agreed to an all stock merger with American Water Works Company. The transaction is expected to close by the end of the first quarter of 2027, following recent shareholder approval. The company is also planning substantial investments in water and natural gas systems and continuing expansion through acquisitions. Essential Utilities focuses on regulated water and natural gas services, a segment that often attracts investors looking for stability and...
NYSE:PNC
NYSE:PNCBanks

A Look At PNC Financial Services Group (PNC) Valuation After Recent Share Price Pullback

Event overview and recent share performance PNC Financial Services Group (PNC) has attracted attention after the stock fell about 4.7% in the latest session and is down roughly 8.9% over the past week. Despite these short term moves, PNC shares show a gain of around 10.4% over the past 3 months and a total return of about 14.7% over the past year, drawing interest from investors tracking regional banks. See our latest analysis for PNC Financial Services Group. With the share price at $212.35,...
NYSE:ASPN
NYSE:ASPNChemicals

A Look At Aspen Aerogels (ASPN) Valuation After Steep Losses And Manufacturing Impairment

Why Aspen Aerogels is back in focus Aspen Aerogels (ASPN) is back on investors’ radar after reporting a sharp year over year revenue decline, a large full year net loss, a sizeable impairment charge, and guidance indicating continued losses. See our latest analysis for Aspen Aerogels. The stock’s recent swings reflect this reset in expectations, with a 7 day share price return showing a 13.57% decline and a 1 year total shareholder return indicating a 59% loss, highlighting how pressure has...